October 2, 2019 / 5:27 AM / a month ago

BRIEF-Novartis Reports Additional Positive Data From Cosentyx Trial

Oct 2 (Reuters) - Novartis:

* POSITIVE 52-WEEK PREVENT DATA CONFIRM COSENTYX® EFFICACY IN ADDRESSING ENTIRE AXSPA SPECTRUM

* PHASE III PREVENT STUDY MET 52-WEEK PRIMARY ENDPOINT OF ASAS40, SHOWING A SUSTAINED RESPONSE IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS

* NOVARTIS PLANS FDA SUBMISSION FOR NR-AXSPA, HAVING SUBMITTED TO EMA PREVIOUSLY Source text for Eikon: Further company coverage: (Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below